Case Reports in Dermatology最新文献

{"title":"Trichological Disorders in Organ Transplant Recipients: Case Report and Literature Review.","authors":"Ewa Kulpińska, Alicja Dębska-Ślizień, Beata Imko-Walczuk","doi":"10.1159/000551649","DOIUrl":"10.1159/000551649","url":null,"abstract":"<p><strong>Introduction: </strong>Kidney transplantation is a life-saving procedure for patients with end-stage renal disease. However, long-term immunosuppressive therapy may lead to adverse effects, including hair disorders.</p><p><strong>Case presentation: </strong>We present the case of a 31-year-old patient who developed significant alopecia following kidney transplantation and initiation of tacrolimus-based immunosuppression. The psychological impact of hair loss led the patient to consider discontinuing treatment. Dermatological evaluation revealed features of androgenetic alopecia and telogen effluvium. A change in immunosuppression from tacrolimus to cyclosporine A resulted in marked improvement in hair regrowth and overall well-being. To support this observation, we conducted a targeted literature review, identifying four case reports linking alopecia to immunosuppressive therapy in solid organ transplant recipients.</p><p><strong>Conclusion: </strong>This case highlights the need for awareness of trichological side effects among transplant clinicians, especially given their potential impact on treatment adherence and patient quality of life. Regular dermatological assessments and individualized management strategies, including the possibility of modifying immunosuppressive regimens, may help reduce these complications.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"302-311"},"PeriodicalIF":0.7,"publicationDate":"2026-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13286502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptional Response of Necrolytic Migratory Erythema to Octreotide in a Patient with Glucagonoma: A Case Report and Scoping Review.","authors":"Gabriela Rozo-Paz, Deyanira González-Devia, Diego Andres Aguirre-Matallana, Juan Guillermo Chalela-Mantilla","doi":"10.1159/000552556","DOIUrl":"10.1159/000552556","url":null,"abstract":"<p><strong>Introduction: </strong>Glucagonomas are rare neuroendocrine neoplasms (NENs) that often present with locoregional involvement at diagnosis and are characterized by variable survival outcomes and diverse therapeutic approaches. We present a clinical case of glucagonoma associated with necrolytic migratory erythema (NME), demonstrating an exceptional response to octreotide. Additionally, a scoping review was conducted to evaluate the efficacy of somatostatin analogs (SSAs) in managing NME.</p><p><strong>Methods: </strong>Through a meticulous search on MEDLINE, we unearthed a collection of case reports and series that shed light on patients with glucagonoma and neuroendocrine tumors (NETs) who received treatment with somatostatin analogs (SSAs). A thorough extraction and analysis of pertinent data was conducted to deepen our understanding of these cases.</p><p><strong>Case presentation: </strong>A 66-year-old woman consulted with a 4-year history of migratory, pruritic, and painful vesiculobullous skin lesions consistent with NME. Laboratory tests revealed serum glucagon levels exceeding 500 pg/mL, and magnetic resonance imaging identified a pancreatic mass with hepatic metastases. Octreotide therapy resulted in the complete resolution of cutaneous lesions within 4 days of the first dose. She chose not to undergo surgery or other treatment options, and as a result, she passed away due to the progression of her disease.</p><p><strong>Results: </strong>Out of a total of 1,712 reviewed cases, 25 met the inclusion criteria. Among these cases, 56% of the patients were female, and the mean age at diagnosis was 59.74 years. Clinical improvement in NME was observed in 80% of patients treated with SSAs, with an average time to resolution of dermatological symptoms being 1.41 months. The median overall survival for these patients was 11 months.</p><p><strong>Conclusion: </strong>Although SSAs demonstrated notable efficacy in the resolution of NME, their impact on overall survival remains limited. These results emphasize the importance of ongoing research and innovation in treating NENs to improve long-term patient outcomes.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"411-425"},"PeriodicalIF":0.7,"publicationDate":"2026-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13354284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nail Squamous Cell Carcinoma Involving the Nail Fold in a Skin of Color Patient: A Case Report.","authors":"Dustine Reich, Cynthia M Magro, Kira Minkis, Shari R Lipner","doi":"10.1159/000552437","DOIUrl":"10.1159/000552437","url":null,"abstract":"<p><strong>Introduction: </strong>Nail squamous cell carcinomas (SCCs) in skin of color (SoC) patients are exceedingly rare, with only 29 cases previously reported.</p><p><strong>Case presentation: </strong>We describe the case of a female Fitzpatrick skin-type V patient who presented with a 3-year history of a hyperpigmented plaque involving the proximal nail fold of her right thumbnail. The patient reported a positive Pap smear for human papillomavirus (HPV) 16 and 18 seventeen years ago and had not received the HPV vaccine. Biopsy showed SCC positive for high-risk HPV, and the patient underwent Mohs surgery.</p><p><strong>Conclusion: </strong>This case adds to only five prior reports of female SoC patients with nail SCC and emphasizes the importance of considering nail SCC in the differential diagnosis of a hyperpigmented nail fold, especially with a history of HPV.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"389-394"},"PeriodicalIF":0.7,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13341100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Subcutaneous Candidiasis Presenting as a Chronic Eschar-Covered Ulcer: A Diagnostic Challenge in an Immunocompromised Host - A Case Report and Literature Review.","authors":"Kumudhavalli Kavanoor Sridhar, Greg J German, Sigmund Krajden, Zared Aziz, Yan Chen, James A Scott, Richard C Summerbell","doi":"10.1159/000552323","DOIUrl":"10.1159/000552323","url":null,"abstract":"<p><strong>Introduction: </strong>Primary subcutaneous candidiasis is a rare, severe opportunistic infection. While <i>Candida albicans</i> is typically a commensal, it can become invasive in immunocompromised hosts, often mimicking other necrotic skin conditions.</p><p><strong>Case presentation: </strong>We describe an 83-year-old male with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia who developed a nonhealing eschar-covered ulcer on his left shin following a minor gardening injury. Despite multiple courses of broad-spectrum antibiotics, the lesion persisted. Initial superficial cultures were dismissed as colonization. However, multiple deep tissue biopsies and high-throughput internal transcribed spacer 2 sequencing confirmed invasive <i>C. albicans</i>. The patient was treated with intravenous Caspofungin for 3 weeks, leading to significant wound healing.</p><p><strong>Conclusion: </strong>This case highlights the diagnostic challenge of \"atypical\" fungal ulcers. It underscores the importance of deep tissue biopsies and molecular sequencing in neutropenic patients to differentiate invasive pathogens from surface colonization and prevent systemic dissemination.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"380-388"},"PeriodicalIF":0.7,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13336724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148435110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baboon Syndrome Triggered by Diclofenac Potassium: A Case Report of Symmetrical Drug-Related Intertriginous and Flexural Exanthema.","authors":"Abdalwahab AlKanderi, Alsadat Mosbeh, Abeer A AlBazali, Ashok K Sharma","doi":"10.1159/000552458","DOIUrl":"10.1159/000552458","url":null,"abstract":"<p><strong>Introduction: </strong>Baboon syndrome, also known as symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), is a rare reaction characterised by distinct, bilateral erythema in the flexural and intertriginous regions, occurring without systemic symptoms.</p><p><strong>Case presentation: </strong>We present a 53-year-old gentleman who, 3 days after commencing diclofenac potassium for knee pain, exhibited symmetrical, well-defined erythema affecting the neck, axillae, cubital and popliteal fossae, forearms, inguinal folds, thighs, legs, and feet. He displayed no systemic symptoms or fever. The time and distinctive distribution of SDRIFE induced by diclofenac potassium were congruent.</p><p><strong>Management and outcome: </strong>Following the cessation of diclofenac potassium, the patient received topical corticosteroids and oral antihistamines. The symptoms resolved after 1 week.</p><p><strong>Conclusion: </strong>This case highlights the necessity for physicians to identify this presentation for prompt diagnosis and care and also indicates diclofenac potassium as a possible cause of SDRIFE.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"372-379"},"PeriodicalIF":0.7,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13331471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab Combined with Glucocorticoids in the Treatment of Pemphigus Vegetans: Case Report.","authors":"Heng Wang, Wenkang Cheng, Shukang Li, Jiyun Tang, Biao Yu, Hualiang Nan, Changpei Lu, Han Zhang, Xueting Zhang, Ting Luo, Xuefei Ke, Haixia Jing","doi":"10.1159/000551428","DOIUrl":"10.1159/000551428","url":null,"abstract":"<p><strong>Introduction: </strong>Vegetative lesions arise from various causes, with typical examples including pemphigus vegetans and pyoderma vegetans (PDV). Differential diagnosis, treatment selection, and long-term management remain challenging. Systemic glucocorticoids are the conventional first-line therapy for pemphigus diseases, often combined with nonspecific immunosuppressants such as cyclosporine. Dupilumab, a monoclonal antibody targeting IL-4Rα, has recently been reported as a potential therapeutic option for pemphigus vegetans.</p><p><strong>Case presentation: </strong>We report a 74-year-old woman presenting with painful perianal nodules, plaques, and ulcers for more than 3 months, accompanied by oral ulcers and weight loss. Skin biopsy demonstrated pseudoepitheliomatous hyperplasia with partial epidermal erosion. Laboratory testing revealed positive pemphigus antibodies, and skin secretion culture isolated <i>Proteus mirabilis</i>. Ambulatory electrocardiography indicated third-degree atrioventricular block. Positron emission tomography-computed tomography showed no evidence of malignancy. The patient was treated with dupilumab combined with systemic glucocorticoids and doxycycline, resulting in progressive shrinkage and eventual healing of the lesions.</p><p><strong>Conclusion: </strong>In cases of vegetative lesions with pseudoepitheliomatous hyperplasia and positive Dsg3 antibodies, pemphigus vegetans should be considered, while PDV and paraneoplastic syndrome must be excluded. For patients with severe comorbidities, dupilumab combined with low-dose glucocorticoids may represent a therapeutic option after careful evaluation of immunosuppressive risks. To our knowledge, this is the first reported case of pemphigus vegetans successfully treated with dupilumab.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"278-283"},"PeriodicalIF":0.7,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13258277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Generalized Pustular Psoriasis Flare with Intravenous Spesolimab Followed by Long-Term Treatment with Subcutaneous Spesolimab: A Case Report.","authors":"Angad Arinder Chadha","doi":"10.1159/000552213","DOIUrl":"10.1159/000552213","url":null,"abstract":"<p><strong>Introduction: </strong>This case report describes the clinical course and treatment of generalized pustular psoriasis (GPP) flare with intravenous (i.v.) spesolimab, an anti-IL-36R antibody, and subsequent long-term disease management with subcutaneous (s.c.) spesolimab.</p><p><strong>Case presentation: </strong>A 72-year-old female patient had an ongoing GPP flare for 1 month before presenting to the hospital for flare and related multiorgan failure. She was successfully treated with 2 infusions of 900 mg i.v. spesolimab 1 week apart. She then initiated therapy with 300 mg s.c. spesolimab every 4 weeks for the long-term treatment of GPP. Rapid and significant improvement of skin and systemic symptoms was observed within 1 week of receiving i.v. spesolimab. However, the severity of the patient's prolonged flare deteriorated her functional status, and she required rehabilitation post-discharge. At follow-ups, s.c. spesolimab demonstrated favorable efficacy and tolerability, with no flare recurrence. Mild superficial desquamation reappeared in the days before consecutive spesolimab doses, with complete skin recovery achieved post-dose.</p><p><strong>Conclusion: </strong>This case underscores the serious complications arising from untreated flare and the need for long-term management of chronic GPP. The patient's ongoing post-flare symptoms highlight the chronicity of GPP, and continuous targeted treatment with spesolimab improved both her symptoms and quality of life.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"363-371"},"PeriodicalIF":0.7,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13327670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148374625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Narrative Case Report of Postherpetic Pseudoabdominal Hernia.","authors":"Shufang Zong, Huiyu Ding","doi":"10.1159/000551695","DOIUrl":"10.1159/000551695","url":null,"abstract":"<p><strong>Background: </strong>Herpes zoster pseudoabdominal hernia (HZV-PAH) is a rare and easily misdiagnosed complication after varicella-zoster virus (VZV) infection, which is essentially a neurogenic muscle dysfunction rather than a true hernia.</p><p><strong>Case presentation: </strong>HZV-PAH refers to the dysfunction of nerves innervating abdominal wall muscles (especially the transversus abdominis and internal oblique muscles) caused by VZV invasion of intercostal or lumbar nerves, leading to local muscle relaxation, paralysis, or bulging, resulting in local bulging of the abdominal wall. This disease is relatively rare, with fewer than 2% of cases of abdominal pseudo-hernia reported after herpes zoster infection, mostly occurring in elderly patients with herpes zoster, those with impaired immunity, or those with extensive involvement of dermatomes.</p><p><strong>Conclusions: </strong>HZV-PAH is a neurogenic muscle disease without anatomical defects of the abdominal wall. Clinicians should improve their awareness of early identification and differential diagnosis to avoid misdiagnosis and unnecessary surgical treatment.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"312-316"},"PeriodicalIF":0.7,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paraneoplastic Pemphigus Associated with Follicular Lymphoma, Sjögren's Syndrome, and Bronchiolitis Obliterans: A Case of Prolonged Survival.","authors":"Miyuki Yamamoto, Norito Ishii, Toshiyuki Yamamoto","doi":"10.1159/000552169","DOIUrl":"10.1159/000552169","url":null,"abstract":"<p><strong>Introduction: </strong>Paraneoplastic pemphigus (PNP), also known as paraneoplastic autoimmune multiorgan syndrome, is a rare and often fatal autoimmune blistering disease associated with hematological malignancies. It is frequently complicated by severe extracutaneous manifestations such as bronchiolitis obliterans.</p><p><strong>Case presentation: </strong>A 67-year-old woman presented with refractory, painful oral erosions and lichenoid skin lesions. Histopathological examination, direct immunofluorescence, and immunoblotting revealed findings consistent with PNP, including antibodies against envoplakin and periplakin. Further evaluation revealed concurrent follicular lymphoma, Sjögren's syndrome, and bronchiolitis obliterans. Combination therapy with systemic corticosteroids and rituximab-based chemotherapy achieved remission of the lymphoma and sustained control of mucocutaneous lesions. The patient survived for 34 months after initial presentation despite progressive respiratory impairment.</p><p><strong>Conclusion: </strong>This case highlights the diagnostic complexity of PNP with overlapping autoimmune features and underscores the importance of early recognition and multidisciplinary management. Despite its typically poor prognosis, rituximab-based therapy may improve survival outcomes by targeting both the underlying malignancy and autoimmune activity.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"355-362"},"PeriodicalIF":0.7,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13322697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148367109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tofacitinib in Overlapping Autoimmune and Autoinflammatory Disorders: A Case Report of a Dual Graham-Little-Piccardi-Lasseur Syndrome and Hidradenitis Suppurativa.","authors":"Navid Namakizadeh Esfahani, Sepehr Boroumand Sani, Kambiz Kamyab Hesari, Sama Heidari, Kamran Balighi","doi":"10.1159/000552170","DOIUrl":"10.1159/000552170","url":null,"abstract":"<p><strong>Introduction: </strong>Graham-Little-Piccardi-Lassueur Syndrome (GLPLS) is an autoimmune disorder characterized by a triad of cicatricial alopecia of the scalp, non-cicatricial alopecia, and follicular eruptions in the axillae and groin. Immune system dysregulation can contribute to associations with other inflammatory diseases.</p><p><strong>Case presentation: </strong>Here, we present a female patient with a history of scalp hair loss and follicular purulent lesions on the trunk. Biopsies from three sample sites on the scalp and trunk confirmed the diagnosis of both GLPLS and hidradenitis suppurativa (HS). Due to a limited response to previous treatments, including immunosuppressants and antibiotics, the patient was considered for tofacitinib 5 mg twice daily. After 6 months of treatment, improvement in hair loss and resolution of trunk lesions were observed. Additionally, no recurrence or adverse events were noted during a 2-year follow-up.</p><p><strong>Conclusion: </strong>This case report underscores the likelihood of co-occurrence of two hard-to-treat disorders, both with autoimmune and autoinflammatory basis, and significant improvement of both diseases with a Janus kinase inhibitor.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"346-354"},"PeriodicalIF":0.7,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}